GLP-1 Medications in South Korea: Insurance Shifts and Health Implications

The landscape of metabolic health treatment in South Korea is undergoing a significant transformation. The recent integration of GLP-1 receptor agonists, specifically Ozempic (semaglutide), into the national health insurance system marks a pivotal shift for patients managing type 2 diabetes and obesity. While these medications offer profound clinical benefits, their rise is creating new challenges for the fitness industry and raising critical questions about muscle preservation in aging populations.

Ozempic and the Korean Reimbursement Market

Starting in February 2026, national health insurance coverage began applying to Ozempic, a glucagon-like peptide-1 (GLP-1) class diabetes treatment. This move provides long-awaited financial relief for patients, although the Ministry of Health and Welfare has established strict clinical guidelines for eligibility.

Eligibility Criteria for Insurance Coverage

To qualify for reimbursement, Ozempic is utilized as a triple combination therapy. Patients must meet the following requirements:

• Failure to achieve a glycosylated hemoglobin (HbA1c) level below 7 percent despite using metformin and a sulfonylurea (SU) for two to four months.
• A body mass index (BMI) of 25 kg/㎡ or higher, or an inability to undergo basal insulin therapy.

Medical specialists have expressed concern that these guidelines may force patients toward older therapies, such as sulfonylureas, which are increasingly avoided due to the risk of hypoglycemia, before they can access more modern GLP-1 treatments.

Clinical Benefits Beyond Blood Sugar Control

The adoption of Ozempic is driven by evidence that its benefits extend beyond glycemic control. Two key clinical trials highlight its systemic impact:

• SUSTAIN 6 Trial: This study found that Ozempic reduced the risk of major adverse cardiovascular events (MACE) by 26 percent compared to a placebo.
• FLOW Phase 3 Trial: This trial demonstrated a 24 percent reduction in the risk of composite renal disease endpoints.

Addressing Obesity and Weight Loss

Beyond diabetes, GLP-1 receptor agonists have been approved for the treatment of obesity by the Ministry of Food and Drug Safety (MFDS) in South Korea and the FDA in the United States. These medications mimic the body’s natural GLP-1 hormone to regulate appetite, promote fullness, and stabilize blood sugar.

Administration Options

Patients typically access this treatment through two primary delivery methods:

• Ozempic: Administered via weekly injection.
• Rybelsus: A daily oral medication available in 3 mg, 7 mg, and 14 mg tablets. It must be taken on an empty stomach with a small amount of water (120 ml or less) to ensure proper absorption.

Common side effects include gastrointestinal symptoms, affecting approximately 30% of users, typically manifesting as nausea or queasiness during the early stages of treatment.

The Impact on Fitness and Muscle Health

The rapid adoption of weight-loss “jabs” has led to unexpected societal and physiological consequences. In South Korea, some reports indicate that the shift toward medication-based weight loss is contributing to the closure of gyms as consumer spending habits change.

The Risk of Muscle Loss

While weight loss is the primary goal, new research warns that GLP-1 drugs may accelerate muscle loss, particularly in older adults. This “safety gap” in early megastudies suggests that weight loss achieved via GLP-1s is not exclusively fat loss. To counteract this, health experts emphasize the necessity of strength training and specific workout splits to ensure a “total transformation” that preserves lean muscle mass while reducing adipose tissue.

Frequently Asked Questions

How does Rybelsus differ from Ozempic?

While both contain semaglutide, Ozempic is a weekly injection, and Rybelsus is a daily oral tablet.

What are the insurance requirements for Ozempic in Korea?

Patients must generally fail a combination of metformin and sulfonylurea for 2-4 months, have an HbA1c $\ge$ 7%, and a BMI $\ge$ 25 kg/㎡.

Can GLP-1 medications cause muscle loss?

Yes, research indicates that these drugs may accelerate muscle loss, particularly in older populations, making resistance exercise critical during treatment.

As South Korea continues to integrate these powerful metabolic tools into its public health system, the focus is likely to shift from simple weight reduction to a more holistic approach that balances glycemic control with the preservation of musculoskeletal health.